Prognostic value of E-cadherin expression and CDH1 promoter methylation in patients with endometrial carcinoma.
The primary aim of this study is to evaluate the clinical significance of E-cadherin protein expression and the methylation status in CDH1 promoter in endometrial cancer. The expression of E-cadherin and methylation in its promoter region was analyzed, retrospectively, in 152 clinical tissue samples from patients with endometrial lesions. We found that the hypermethylation of CDH1 promoter, which caused low expression of E-cadherin in endometrial cancer, was associated with not only clinicopathological progress of endometrial cancer but also with the overall 5-year clinical survival rate. The findings provide the potential therapeutic and prognostic target molecule for patients with endomethrial cancer.
Yi
Tie-Zhong
TZ
Department of Obstetrics and Gynecology, the First Affiliated Hospital, Harbin Medical University, Harbin, China.
Guo
Jing
J
Zhou
Lili
L
Chen
Xing
X
Mi
Ruo-Ran
RR
Qu
Quan-Xin
QX
Zheng
Jian-Hua
JH
Zhai
Ling
L
D015703:Antigens, CD; D015820:Cadherins / Q000032:analysis* / Q000235:genetics*; D002277:Carcinoma / Q000737:chemistry* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D002681:China; D019175:DNA Methylation; D015536:Down-Regulation; D016889:Endometrial Neoplasms / Q000737:chemistry* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D011401:Promoter Regions, Genetic; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors
D015703:Antigens, CD; C513384:CDH1 protein, human; D015820:Cadherins